Coming off what it’s described as its “best year ever,” the continuous glucose monitoring provider Dexcom is now looking to expand its work among people with Type 2 diabetes in a new, wider ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback